Tag: Parkinson’s

Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson disease

Highest versus lowest decile of application of simazine, lindane, atrazine linked to increased relative risks for Parkinson disease

PDQ-8 and ADL worsened in standard-of-care medication group, remained stable in stimulation group

All nine LBD+ participants had low 18F-dopamine-derived radioactivity before or at the time of diagnosis of central LBD

Improvements seen in motor and nonmotor symptoms, reductions in disability and complications

Findings persist across demographic groups and independent of depression and other prominent risk factors, including genetic risk

Performance better than certified rater but not quite as good as expert neurologists

Protective HLA-DRB1*04 subtypes bind strongly to aggregation-prone tau PHF6 sequence when acetylated at K311

Gastroparesis, dysphagia, constipation, and IBS without diarrhea are associated with PD in case-control, cohort analyses

Findings seen among patients with prevalent PD in the AlzEye cohort and for incident PD in the U.K. Biobank cohort